Serum bone GLA protein in streak gonad syndrome

Zseli, J; Bosze, P [Bősze, Péter (Szülészet, nőgyóg...), szerző]; Lakatos, P [Lakatos, Péter (Osteológia, endok...), szerző] I. Sz. Belgyógyászati Klinika (SE / AOK / K); Vargha, P; Tarjan, G; Kollin, E; Horvath, C [Horváth, Csaba (Belgyógyászat, en...), szerző] I. Sz. Belgyógyászati Klinika (SE / AOK / K); Laszlo, J; Hollo, I

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: CALCIFIED TISSUE INTERNATIONAL 0171-967X 1432-0827 48 (6) pp. 387-391 1991
      Osteoporosis is one of the most common complications of streak gonad syndrome (SGS), however its pathogenesis is still unclear. Bone Gla protein (BGP) has been found to be a serum marker of bone turnover in various metabolic disease states. In the present study serum BGP and alkaline phosphatase (AP) were measured in 13 osteoporotic patients with SGS and in 56 healthy women. Mean (±SD) serum BGP levels were normal (7.5 ± 2.0 ng/ml) in seven patients who had been on estrogen-progestin replacement therapy and became significantly elevated (P < 0.001) 2 and 3 months after discontinuation of the treatment (15.3 ± 2.3 and 13.2 ± 1.0 ng/ml, respectively). Mean (±SD) serum AP (207 ± 65 U/l) showed significant increases (P < 0.05) 2 months after withdrawal of hormonal substitution (287 ± 74 U/l). Mean (±SD) serum BGP (15.4 ± 3.5) and AP (287 ± 49) levels were significantly higher (P < 0.001 and < 0.05, respectively) in six patients with SGS who had not been on hormonal substitution. These findings are consistent with those obtained in postmenopausal women suffering from ''high remodelling osteoporosis'' and suggest that bone turnover in osteoporotic patients with SGS is increased and the skeletal loss is a consequence of accelerated bone loss rather than decreased bone formation.
      Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
      2021-05-11 06:46